Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind Randomized Parallel Group Study of the Efficacy and Safety of Tesevatinib in Subjects With Autosomal Dominant Polycystic Kidney Disease

NCT03203642 is registered in ClinicalTrials.gov with Kadmon, a Sanofi Company as lead sponsor.

NCT NCT03203642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03203642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind Randomized Parallel Group Study of the Efficacy and Safety of Tesevatinib in Subjects With Autosomal Dominant Polycystic Kidney Disease
Lead sponsor
Kadmon, a Sanofi Company
Phase
Phase 2
Overall status
Completed
Start date
October 12, 2017
Completion date
January 25, 2022
Enrollment
80 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

adpkd, autosomal dominant polycystic kidney